| 28th Mar 2024 7:00 am |
RNS |
Savolitinib sNDA Accepted in China |
| 22nd Mar 2024 7:00 am |
RNS |
Initiation of Registration Stage of P2/3 Trial |
| 14th Mar 2024 9:00 am |
RNS |
LTIP and Share Option Scheme |
| 5th Mar 2024 8:30 am |
RNS |
Vesting of awards under the LTIP |
| 28th Feb 2024 12:45 pm |
RNS |
Publication of Form 20-F |
| 28th Feb 2024 11:30 am |
RNS |
2023 Full Year Results and Business Updates |
| 7th Feb 2024 7:00 am |
RNS |
Presentation of Phase III Data on Fruquintinib |
| 2nd Feb 2024 8:37 am |
RNS |
Inmagene Exercises Option for Two Drug Candidates |
| 1st Feb 2024 8:30 am |
RNS |
HUTCHMED to Announce 2023 Final Results |
| 30th Jan 2024 7:12 am |
RNS |
HUTCHMED Receives Marketing Approval in Hong Kong |
| 11th Jan 2024 7:00 am |
RNS |
Sovleplenib NDA Granted Priority Review in China |
| 29th Dec 2023 8:30 am |
RNS |
Total Voting Rights |
| 29th Dec 2023 8:30 am |
RNS |
Blocklisting Six Monthly Return |
| 21st Dec 2023 10:00 am |
RNS |
Overseas Regulatory Announcement |
| 13th Dec 2023 7:00 am |
RNS |
Inclusion in National Reimbursement Drug List |
| 13th Dec 2023 7:00 am |
RNS |
Completed Enrollment of Phase II/III Trial |
| 7th Dec 2023 10:04 am |
RNS |
Overseas Regulatory Announcement |
| 1st Dec 2023 7:00 am |
RNS |
Clinical Data to be Presented at Congresses |
| 30th Nov 2023 8:30 am |
RNS |
Total Voting Rights |
| 9th Nov 2023 7:00 am |
RNS |
U.S. FDA Approval of FRUZAQLAâ„¢ (fruquintinib) |
| 24th Oct 2023 9:30 am |
RNS |
Vesting of awards under the LTIP |
| 16th Oct 2023 9:30 am |
RNS |
Clinical Data to be Presented at ESMO 2023 |
| 29th Sep 2023 9:30 am |
RNS |
NDA Submission for Fruquintinib in Japan |
| 29th Sep 2023 9:30 am |
RNS |
Total Voting Rights |
| 14th Sep 2023 9:30 am |
RNS |
Director’s Share Dealing |
| 12th Sep 2023 9:30 am |
RNS |
Phase IIIb Savolitinib Results at WCLC 2023 |
| 12th Sep 2023 7:00 am |
RNS |
Patient Enrollment Completed for Bridging Study |
| 31st Aug 2023 9:30 am |
RNS |
Total Voting Rights |
| 29th Aug 2023 7:00 am |
RNS |
BTD in China for Savolitinib for Gastric Cancer |
| 21st Aug 2023 7:00 am |
RNS |
Sovleplenib Phase 3 Study Meets Primary Endpoint |
| 7th Aug 2023 9:30 am |
RNS |
Exercise of Share Options by a Director |
| 31st Jul 2023 12:00 pm |
RNS |
Interim Results and Business Updates |
| 20th Jul 2023 7:00 am |
RNS |
Breakthrough Therapy Designation for Fruquintinib |
| 13th Jul 2023 9:30 am |
RNS |
Changes to Board and Technical Committee |
| 10th Jul 2023 7:00 am |
RNS |
Phase 1 Study of HMPL-415 Initiated |
| 29th Jun 2023 9:30 am |
RNS |
Blocklisting Six Monthly Return |
| 26th Jun 2023 9:30 am |
RNS |
HUTCHMED to Announce 2023 Half-Year Results |
| 16th Jun 2023 7:00 am |
RNS |
Phase III FRESCO-2 Results in The Lancet |
| 15th Jun 2023 3:39 pm |
RNS |
MAA of Fruquintinib Validated by the EMA |
| 9th Jun 2023 10:30 am |
RNS |
HUTCHMED Highlights Presentations at EHA and ICML |
